Pancreatic ductal adenocarcinoma (PDAC) is asymptomatic and metastasizes early, leading to a meager 5-year survival rate of ~7%. Chemotherapy has had limited success in extending the life span of patients with advanced PDAC. Dr. Abdalla and his group are extending their expertise in reactive oxygen species by hypothesizing that inhibition of heme oxygenase in combination with nab-Paclitaxel-Gemcitabine chemotherapy functions to inhibit PDAC growth and metastasis. Dr. Abdalla received a multi-year RSG from ACS so that him and his team can conduct this important research.
Dr. Abdalla receives Research Scholar Grant from the American Cancer Society
Dr. Maher Abdalla front and center with his lab team